Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperoxaluria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Hyperoxaluria. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-003547-38 Sponsor Protocol Number: ALLN-177-206 Start Date*: 2018-07-17
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia
    Medical condition: Enteric or primary hyperoxaluria and hyperoxalemia
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015817-31 Sponsor Protocol Number: OC3-DB-02 Start Date*: 2009-12-01
    Sponsor Name:OxThera IP AB
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006187-30 Sponsor Protocol Number: OC3-OL-01 Start Date*: 2008-06-11
    Sponsor Name:OxThera, Inc.
    Full Title: An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003134-24 Sponsor Protocol Number: ALN-GO1-002 Start Date*: 2017-12-28
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-005606-22 Sponsor Protocol Number: OC5-DB-01 Start Date*: 2013-07-10
    Sponsor Name:OxThera AB
    Full Title: A Phase 1/2, randomised, placebo-controlled, double-blind, multi-centre study to evaluate the efficacy and safety of OC5 to reduce urinary oxalate in subjects with primary hyperoxaluria
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001981-40 Sponsor Protocol Number: ALN-GO1-003 Start Date*: 2018-11-20
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults with Primary Hypero...
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000344-67 Sponsor Protocol Number: DCR-PHXC-104 Start Date*: 2020-08-07
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hype...
    Medical condition: Primary Hyperoxaluria Type 3
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004014-17 Sponsor Protocol Number: ALN-GO1-004 Start Date*: 2019-03-01
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002328-14 Sponsor Protocol Number: OC3-DB-01 Start Date*: 2008-01-10
    Sponsor Name:OxThera Inc.
    Full Title: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary H...
    Medical condition: primary hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020703 Hyperoxaluria LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003142-51 Sponsor Protocol Number: DCR-PH1-101 Start Date*: 2016-04-11
    Sponsor Name:Dicerna Pharmaceuticals, Inc.
    Full Title: A Phase 1 Study of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
    Medical condition: Primary Hyperoxaluria Type 1
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001083-16 Sponsor Protocol Number: DCR-PHXC-203 Start Date*: 2021-10-04
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relativ...
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004407-23 Sponsor Protocol Number: ALN-GO1-001 Start Date*: 2016-02-10
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy...
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002826-97 Sponsor Protocol Number: DCR-PHXC-204 Start Date*: 2021-01-29
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Not Authorised) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003534-89 Sponsor Protocol Number: DCR-PHXC-101 Start Date*: Information not available in EudraCT
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi Center Study in Patients with Primary Hyperoxaluria to Evaluate the Safety, Tolerab...
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003099-10 Sponsor Protocol Number: DCR-PHXC-301 Start Date*: 2019-06-12
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Ongoing) NL (Ongoing) ES (Ongoing) PL (Completed) IT (Ongoing) RO (Completed) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000921-29 Sponsor Protocol Number: ALLN-177-302 Start Date*: 2019-11-12
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
    Medical condition: Enteric Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001346-17 Sponsor Protocol Number: ALN-GO1-005 Start Date*: Information not available in EudraCT
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) BE (Ongoing) NL (Ongoing) Outside EU/EEA IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015217-52 Sponsor Protocol Number: Uni-Koeln-1251 Start Date*: 2010-06-08
    Sponsor Name:University of Cologne
    Full Title: Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate
    Medical condition: In this study we will prospectively analyze the reduction of urinary oxalate excretion under the treatment with PLP in dosages of 5mg/kg/day up to 20 mg/kg/day and serum level response relationship...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037671 Pyridoxine deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004368-74 Sponsor Protocol Number: OC5-OL-01 Start Date*: 2014-03-17
    Sponsor Name:OxThera Intellectual Property AB
    Full Title: A phase 2 open-label multi-centre study to evaluate the efficacy and safety of Oxabact® to reduce plasma oxalate in patients with primary hyperoxaluria who are on dialysis
    Medical condition: Primary Hyperoxaluria (PH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003098-91 Sponsor Protocol Number: DCR-PHXC-201 Start Date*: 2019-03-05
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyper...
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA